{"favorite_id": 10389, "calc_type": "", "dosing": false, "full_title_en": "Immune-Related Adverse Events for GI Toxicity - Hepatitis", "short_title_en": "IRAE for GI Toxicity - Hepatitis", "medium_description_en": "Grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.", "short_description_en": "Grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.", "before_use": "", "instructions_en": "<p>Use in adult patients with symptoms of hepatitis or AST, ALT, or total bilirubin elevation that developed while on treatment with immune checkpoint inhibitors.</p>", "purpose_en": ["Diagnosis", "Prognosis"], "disease_en": ["Hepatitis"], "specialty_en": ["Allergy and Immunology", "Gastroenterology", "Hepatology", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Abdominal Pain", "Fever", "Jaundice"], "system_en": ["Gastrointestinal", "Hepatic"], "search_abbreviation_en": ["Immune Related Adverse Events, irae, hepatitis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"], "slug": "immune-related-adverse-events-gi-toxicity-hepatitis", "seo": {"meta_description_en": "The Immune-Related Adverse Events for GI Toxicity - Hepatitis grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.", "keywords_en": "Immune Related Adverse Events, irae, hepatitis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"}, "content": {"how_to_use": {"use_case_en": "<p>Adult patients with hepatitis symptoms or AST, ALT, or total bilirubin elevation, while on treatment with immune checkpoint inhibitors including agents against PD-1 (i.e. pembrolizumab, nivolumab), PD-L1 (i.e. atezolizumab, avelumab, durvalumab), or CTLA-4 (i.e. ipilimumab).</p>", "pearls_pitfalls_en": "<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) hepatitis should be suspected in patients with symptoms of hepatitis (i.e., jaundice, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark (tea-colored) urine, easy bleeding or bruising, anorexia) while on treatment with immune checkpoint inhibitors.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May occur any time during immune checkpoint inhibitor treatment, but most frequently seen 6-12 weeks following treatment initiation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">More frequently seen with anti-CTLA-4 agents, but is also an important adverse event caused by anti-PD-1 and anti-PD-L1 agents.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Management of immune checkpoint inhibitor hepatitis is based on the grade of hepatitis.</p>\n</li>\n</ul>", "why_use_en": "<p>ICPi hepatitis is the third most common cause of hospital admissions due to immune related adverse events. This tool aids in the decision of immune checkpoint inhibitor discontinuation, further diagnostic work-up, and immunosuppressant treatment initiation.</p>"}, "next_steps": {"advice_en": "<p>Monitor patients for abnormal liver blood tests: AST, ALT, and bilirubin prior to each infusion.&nbsp;</p>\n<p><strong>Grade 1:&nbsp;</strong>Monitor patient for abnormal liver blood tests: AST, ALT, and bilirubin once or twice weekly.</p>\n<p><strong>Grade 2-4:&nbsp;</strong>Further diagnostic work-up is recommended as following:&nbsp;</p>\n<ul>\n<li>Work-up for other causes of elevated liver enzymes, including viral hepatitis, alcohol history, iron studies, thromboembolic event, liver ultrasound, cross-sectional imaging for potential liver metastasis from primary malignancy. Consider antinuclear antibodies, antismooth muscle antibodies, antineutrophil cytoplasmic antibodies if suspicion for primary autoimmune hepatitis is high.</li>\n<li>Work-up for other etiologies: consider checking creatine kinase for isolated elevation of transaminases.</li>\n</ul>", "management_en": "<p dir=\"ltr\">For all patients where an IRAE diagnosis is being considered, it is always recommended to involve the specialist or team prescribing the immune checkpoint therapy.</p>\n<p dir=\"ltr\"><strong>All patients</strong></p>\n<ul>\n<li dir=\"ltr\">Counsel all patients to be aware of and inform their health care provider immediately if they experience any of the following:\n<ul>\n<li dir=\"ltr\">Yellowing of skin or whites of the eyes, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, feeling less hungry than usual.</li>\n</ul>\n</li>\n</ul>\n<p dir=\"ltr\"><strong>Grade 1:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Continue immune checkpoint inhibitor with close monitoring.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider alternate etiologies.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor laboratories one to two times weekly.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Manage with supportive care for symptom control.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 2:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Hold immune checkpoint inhibitor temporarily and resume if recovers to grade 1 or less on prednisone &le; 10 mg/d.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">For patients with symptoms, consider corticosteroid 0.5&ndash;1 mg/kg/d prednisone or equivalent if the abnormal elevation persists with significant clinical symptoms in 3&ndash;5 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Increase frequency of monitoring to every 3 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Infliximab might not be the most appropriate treatment option in the situation of immune-mediated hepatitis given the potential risk of idiosyncratic liver failure (Note: No clear evidence shows the liver toxicity from infliximab from other studies).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">In follow-up, may resume immune checkpoint inhibitor treatment followed by taper only when symptoms improve to G1 or less and corticosteroid &le; 10 mg/d; taper over at least 1 month.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Patients should be advised to stop unnecessary medications and any known hepatotoxic drugs.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 3:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Often corticosteroid 1&ndash;2 mg/kg methylprednisolone or equivalent is recommended.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If corticosteroid refractory or no improvement after 3 days, consider mycophenolate mofetil or azathioprine (if using azathioprine should test for thiopurine methyltransferase deficiency).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Laboratories at daily or every other day; consider inpatient monitoring for patients with AST/ALT &gt; 8 &times; ULN and/or elevated TB 3 &times; ULN Increase frequency of monitoring to every 1&ndash;2 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Infliximab might not be the most appropriate treatment option in the situation of immune-mediated hepatitis given the potential risk of liver failure (Note: No clear evidence shows that the liver toxicity from infliximab from other studies); alternatives include non&ndash;TNF-&alpha; agents as systemic immunosuppressants.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Corticosteroid taper can be attempted around 4&ndash;6 weeks; re-escalate if needed; optimal duration unclear.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 4:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Permanently discontinue immune checkpoint inhibitor.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Steroid 2 mg/kg/d methylprednisolone equivalents should be considered.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If corticosteroid refractory or no improvement after 3 days, consider mycophenolate mofetil.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor laboratories daily; consider inpatient monitoring.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Avoid the use of infliximab in the situation of immune-mediated hepatitis.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consult hepatology if no improvement was achieved with corticosteroid.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Corticosteroid taper can be attempted around 4&ndash;6 weeks when symptoms improve to G1 or less; re-escalate if needed; optimal duration unclear.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider transfer to tertiary care facility if necessary.</p>\n</li>\n</ol>\n<p><span id=\"docs-internal-guid-d3c7f420-7fff-1ee8-32d7-dd2494c14bb4\">See&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29442540\" target=\"_blank\" rel=\"noopener\">Brahmer 2018</a>&nbsp;for full ASCO guidelines.</p>", "critical_actions_en": "<p>Infliximab, as an immunosuppressant, might not be the most appropriate treatment option due to potential risk of liver failure despite no clinical evidence in the literature; alternatives include non&ndash;TNF-&alpha; agents as systemic immunosuppressants.</p>"}, "about": {"formula_en": "<div dir=\"ltr\" align=\"left\"><br class=\"Apple-interchange-newline\" />\n<table><colgroup><col width=\"258\" /><col width=\"190\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Hepatitis grade</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Asymptomatic (AST or ALT &gt; ULN to 3.0 x ULN and/or total bilirubin &gt; ULN to 1.5 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Asymptomatic (AST or ALT &gt; ULN to 3.0 to 5 x ULN and/or total bilirubin &gt;1.5 to &le;3 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Symptomatic liver dysfunction, fibrosis by biopsy, compensated cirrhosis, reactivation of chronic hepatitis (AST or ALT 5-20 x ULN and/or total bilirubin 3-10 x ULN)&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">G3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Decompensated liver function leg, ascites, coagulopathy, encephalopathy, coma; AST or ALT &gt;20 x ULN and/or total bilirubin &gt;10 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">See Next Steps for details on management.</p>", "more_info_en": "", "evidence_based_medicine_en": "<p>Guidelines for IRAE in GI toxicity (hepatitis) were developed by a multidisciplinary, multi-organizational panel of experts in medical oncology based on a systematic review of the medical literature.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/29442540 ", "text": "Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Nazli", "img": "", "lastName": "Dizman", "name": "Nazli Dizman, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Julie R. Brahmer", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Julie R. Brahmer, MSc, MD, is the co-director of the upper aerodigestive department at Johns Hopkins Medicine in Baltimore, MD. She is also a professor of oncology at Johns Hopkins Medicine. Dr. Brahmer\u2019s primary research is focused on treatment of lung cancer and mesothelioma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-julie-brahmer.png", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Brahmer+JR%5BAuthor%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Criteria", "default": null, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "Asymptomatic (AST or ALT > ULN to 3.0 x ULN and/or total bilirubin > ULN to 1.5 x ULN)", "value": 1}, {"label": "Asymptomatic (AST or ALT > ULN to 3.0 to 5 x ULN and/or total bilirubin >1.5 to \u22643 x ULN)", "value": 2}, {"label": "Symptomatic liver dysfunction, fibrosis by biopsy, compensated cirrhosis, reactivation of chronic hepatitis (AST or ALT 5-20 x ULN and/or total bilirubin 3-10 x ULN)", "value": 3}, {"label": "Decompensated liver function leg, ascites, coagulopathy, encephalopathy, coma; AST or ALT >20 x ULN and/or total bilirubin >10 x ULN)", "value": 4}], "name": "grading"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 10378, "short_title_en": "IRAE for Renal Toxicities - Nephritis", "slug": "immune-related-adverse-events-renal-toxicities-nephritis"}, {"calcId": 10377, "short_title_en": "IRAE for Endocrine Toxicities - Diabetes", "slug": "immune-related-adverse-events-endocrine-toxicities-diabetes-mellitus"}, {"calcId": 10383, "short_title_en": "IRAE for Lung Toxicity - Pneumonitis", "slug": "immune-related-adverse-events-lung-toxicity-pneumonitis"}]}